These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24316629)

  • 1. JDRF teams with VC PureTech to promote startups.
    Orelli B
    Nat Biotechnol; 2013 Dec; 31(12):1065. PubMed ID: 24316629
    [No Abstract]   [Full Text] [Related]  

  • 2. Michigan's next wave of biopharmaceutical entrepreneurship.
    Kerppola R; van de Walle M; Surine S
    Nat Biotechnol; 2003 Sep; 21(9):1109-11. PubMed ID: 12949575
    [No Abstract]   [Full Text] [Related]  

  • 3. Swedish roadtrip.
    Herrera S
    Nat Biotechnol; 2006 Jan; 24(1):15. PubMed ID: 16475247
    [No Abstract]   [Full Text] [Related]  

  • 4. Earlier stage biotechs attract partners.
    Ratner M
    Nat Biotechnol; 2005 May; 23(5):509. PubMed ID: 15877052
    [No Abstract]   [Full Text] [Related]  

  • 5. Japanese firms broaden investment focus to early biotech.
    Louët S; Sipp D
    Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
    [No Abstract]   [Full Text] [Related]  

  • 6. Benefits of biotech clusters questioned.
    Sheridan C
    Nat Biotechnol; 2003 Nov; 21(11):1258-9. PubMed ID: 14595343
    [No Abstract]   [Full Text] [Related]  

  • 7. The term sheet tango.
    Willey T; Parsigian D
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE29-30. PubMed ID: 12874974
    [No Abstract]   [Full Text] [Related]  

  • 8. Giving your spinout the right spin.
    McElroy D
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE39-41. PubMed ID: 12874978
    [No Abstract]   [Full Text] [Related]  

  • 9. Filters for preparing to meet a venture capitalist.
    Christoffersen R
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE49-50. PubMed ID: 12874981
    [No Abstract]   [Full Text] [Related]  

  • 10. Convincing a venture capitalist to invest in your idea.
    Dooley JF; Dooley JF
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE45-8. PubMed ID: 12874980
    [No Abstract]   [Full Text] [Related]  

  • 11. Why media relations matter.
    Kureczka JE
    Nat Biotechnol; 2006 Apr; 24(4):387-9. PubMed ID: 16710903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exiting this year and into the next.
    Nat Biotechnol; 2005 Dec; 23(12):1451. PubMed ID: 16333272
    [No Abstract]   [Full Text] [Related]  

  • 13. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 14. The closure of Sugen.
    Levitzki A
    Nat Biotechnol; 2003 Sep; 21(9):969. PubMed ID: 12949548
    [No Abstract]   [Full Text] [Related]  

  • 15. Stelios Papadopoulos.
    Papadopoulos S
    Nat Biotechnol; 2011 Mar; 29(3):184. PubMed ID: 21390003
    [No Abstract]   [Full Text] [Related]  

  • 16. Biotech parks proliferate, despite concerns over sustainability.
    Jia H; Jayaraman KS; Orellana C
    Nat Biotechnol; 2003 Nov; 21(11):1259-60. PubMed ID: 14595344
    [No Abstract]   [Full Text] [Related]  

  • 17. UK biotech sector loses flagship PowderJect to Chiron.
    Mitchell P
    Nat Biotechnol; 2003 Jul; 21(7):717. PubMed ID: 12833073
    [No Abstract]   [Full Text] [Related]  

  • 18. Selling out.
    Martin JF
    Nat Biotechnol; 2010 Apr; 28(4):315-7. PubMed ID: 20383912
    [No Abstract]   [Full Text] [Related]  

  • 19. Big pharma wants you.
    Mack GS
    Nat Biotechnol; 2006 Nov; 24(11):1317-9. PubMed ID: 17162751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The promise of the East: India and China as R&D options.
    Goodall S; Janssens B; Wagner K; Wong J; Woods W; Yeh M
    Nat Biotechnol; 2006 Sep; 24(9):1061-4. PubMed ID: 17061321
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.